SG11202102058UA - Cardiac cell reprogramming with myocardin and ascl1 - Google Patents
Cardiac cell reprogramming with myocardin and ascl1Info
- Publication number
- SG11202102058UA SG11202102058UA SG11202102058UA SG11202102058UA SG11202102058UA SG 11202102058U A SG11202102058U A SG 11202102058UA SG 11202102058U A SG11202102058U A SG 11202102058UA SG 11202102058U A SG11202102058U A SG 11202102058UA SG 11202102058U A SG11202102058U A SG 11202102058UA
- Authority
- SG
- Singapore
- Prior art keywords
- myocardin
- ascl1
- cardiac cell
- cell reprogramming
- reprogramming
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1719—Muscle proteins, e.g. myosin or actin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862725168P | 2018-08-30 | 2018-08-30 | |
US201962788479P | 2019-01-04 | 2019-01-04 | |
US201962852746P | 2019-05-24 | 2019-05-24 | |
PCT/US2019/049150 WO2020047467A2 (fr) | 2018-08-30 | 2019-08-30 | Reprogrammation de cellules cardiaques avec la myocardine et ascl1 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202102058UA true SG11202102058UA (en) | 2021-03-30 |
Family
ID=69643073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102058UA SG11202102058UA (en) | 2018-08-30 | 2019-08-30 | Cardiac cell reprogramming with myocardin and ascl1 |
Country Status (11)
Country | Link |
---|---|
US (3) | US11015211B2 (fr) |
EP (1) | EP3843774A4 (fr) |
JP (2) | JP7450945B2 (fr) |
KR (1) | KR20210102870A (fr) |
CN (1) | CN113164556A (fr) |
AU (2) | AU2019333315B2 (fr) |
BR (1) | BR112021003897A2 (fr) |
CA (1) | CA3111076A1 (fr) |
IL (1) | IL281145A (fr) |
SG (1) | SG11202102058UA (fr) |
WO (1) | WO2020047467A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2571704A (en) * | 2018-02-22 | 2019-09-11 | Georg August Univ Gottingen Stiftung Offentlichen Rechts Univer Sitatsmedzin Goettingen | Prevention or treatment of cardiac arrhytmia and sudden cardiac death |
BR112021003897A2 (pt) | 2018-08-30 | 2021-05-25 | Tenaya Therapeutics, Inc. | reprogramação de células cardíacas com miocarina e asci1 |
US20230137971A1 (en) * | 2019-07-11 | 2023-05-04 | Tenaya Therapeutics Inc. | Cardiac cell reprogramming with micrornas and other factors |
WO2022022624A1 (fr) * | 2020-07-29 | 2022-02-03 | 南京昕瑞再生医药科技有限公司 | Procédé de production de cardiomyocytes par reprogrammation |
EP4298215A1 (fr) * | 2021-02-25 | 2024-01-03 | Tenaya Therapeutics, Inc. | Séquences activatrices spécifiques de fibroblastes cardiaques et leurs méthodes d'utilisation |
WO2023283649A1 (fr) * | 2021-07-08 | 2023-01-12 | Tenaya Therapeutics, Inc. | Cassettes d'expression optimisées pour thérapie génique |
KR20240090030A (ko) * | 2022-11-25 | 2024-06-21 | 고려대학교 산학협력단 | 방사선 치료에 의하여 손상된 근육 재생을 위한 고기능성 세포 치료제 조성물 |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4962091A (en) | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
US5591624A (en) | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
US7070994B2 (en) | 1988-03-21 | 2006-07-04 | Oxford Biomedica (Uk) Ltd. | Packaging cells |
JP3082204B2 (ja) | 1988-09-01 | 2000-08-28 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5817491A (en) | 1990-09-21 | 1998-10-06 | The Regents Of The University Of California | VSV G pseusdotyped retroviral vectors |
US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
EP0752885B1 (fr) | 1992-09-25 | 2003-07-09 | Neorx Corporation | Inhibiteur therapeutique de cellules des muscles vasculaires lisses |
JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
WO1995000655A1 (fr) | 1993-06-24 | 1995-01-05 | Mc Master University | Vecteurs a base d'adenovirus destines a la therapie genique |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
HU223733B1 (hu) | 1993-10-25 | 2004-12-28 | Canji, Inc. | Rekombináns adenovírus vektor és eljárás alkalmazására |
US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
FR2751345B1 (fr) | 1996-07-16 | 1998-09-18 | Univ Paris Curie | Lignees d'encapsidation hautement productrices |
US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
EP0932694A2 (fr) | 1996-09-11 | 1999-08-04 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vecteur de vaa4 et ses utilisations |
US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
WO1999027946A1 (fr) | 1997-12-02 | 1999-06-10 | Chong Kun Dang Corp. | Preparation pharmaceutique comportant une microemulsion de cyclosporine a l'etat solide |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
US6254890B1 (en) | 1997-12-12 | 2001-07-03 | Massachusetts Institute Of Technology | Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US6984517B1 (en) | 1998-05-28 | 2006-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector and uses thereof |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
EP1186655B1 (fr) | 1999-06-01 | 2008-04-09 | Chugai Seiyaku Kabushiki Kaisha | Cellule d' empaquetage |
WO2001083692A2 (fr) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Vecteurs aav recombinants dotes de capsides aav5 et vecteurs aav5 pseudotypes dans des capsides heterologues |
CA2410828C (fr) | 2000-06-01 | 2012-01-24 | University Of North Carolina At Chapel Hill | Vecteurs de parvovirus dupliques |
AU2001289852A1 (en) | 2000-08-31 | 2002-03-13 | Edwin Lundgren | Control device for a steering kite on a boat |
US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
US7427394B2 (en) | 2000-10-10 | 2008-09-23 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
WO2002060946A2 (fr) * | 2000-12-21 | 2002-08-08 | Board Of Regents, The University Of Texas System | Methodes et compositions relatives a un facteur nucleaire regulateur specifique du muscle cardiaque |
US6962798B2 (en) * | 2000-12-21 | 2005-11-08 | Board Of Regents, The University Of Texas System | Methods and compositions relating to a cardiac-specific nuclear regulatory factor |
US6962815B2 (en) | 2001-01-05 | 2005-11-08 | Children's Hopital Inc. | AAV2 vectors and methods |
WO2002103028A2 (fr) * | 2001-05-30 | 2002-12-27 | Biomedical Center | Criblage in silico de sequences exprimees associees a un phenotype |
SG10201912509RA (en) | 2001-11-13 | 2020-02-27 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
EP1453547B1 (fr) | 2001-12-17 | 2016-09-21 | The Trustees Of The University Of Pennsylvania | Sequences du serotype 8 du virus associe a l'adenovirus (aav), vecteurs les contenant et utilisations correspondantes |
AU2002359284A1 (en) | 2001-12-17 | 2003-06-30 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor |
US8105652B2 (en) | 2002-10-24 | 2012-01-31 | Massachusetts Institute Of Technology | Methods of making decomposable thin films of polyelectrolytes and uses thereof |
US7485291B2 (en) | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
US7727969B2 (en) | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
ES2629087T3 (es) | 2003-06-19 | 2017-08-07 | Genzyme Corporation | Viriones de AAV con inmunorreactividad reducida y usos de los mismos |
US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
CN102212558B (zh) | 2003-09-30 | 2016-08-03 | 宾夕法尼亚大学托管会 | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 |
FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
JP4553355B2 (ja) | 2004-10-04 | 2010-09-29 | 富士フイルム株式会社 | トリパノソーマ原虫寄生感染症の予防又は治療用医薬組成物 |
WO2007001448A2 (fr) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Particules polymeres revetues a diffusion regulee comme vecteurs efficaces d'administration par voie orale de produits biopharmaceutiques |
CN106906241B (zh) | 2005-04-07 | 2020-09-11 | 宾夕法尼亚大学托管会 | 增强腺相关病毒载体功能的方法 |
US7968698B2 (en) | 2005-05-25 | 2011-06-28 | The Regents Of The University Of California | Optimized core promoters and uses thereof |
SI2002003T1 (sl) | 2005-05-27 | 2016-05-31 | Ospedale San Raffaele S.R.L. | Genski vektor, ki vsebuje mi-RNA |
CN101346468B (zh) | 2005-06-15 | 2016-03-30 | 麻省理工学院 | 含胺脂质和其用途 |
DE102005035527A1 (de) | 2005-07-26 | 2007-02-08 | Basf Ag | Verwendung von Tetrahydrobenzoxazinen als Stabilisatoren |
US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
EP2671949A1 (fr) | 2005-12-12 | 2013-12-11 | University Of North Carolina At Chapel Hill | Micro-ARN miR-145 régulant la prolifération et la différenciation des cellules musculaires |
WO2007070682A2 (fr) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | Systeme de criblage de particules |
WO2007089632A2 (fr) | 2006-01-27 | 2007-08-09 | The University Of North Carolina At Chapel Hill | Vecteurs chimères de liaison à l'héparine et au sulfate d'héparane |
WO2008016391A2 (fr) | 2006-01-31 | 2008-02-07 | The Board Of Trustees Of The Leland Stanford Junior University | Vecteurs parvoviraux auto-complémentaires et leurs procédés de fabrication et d'utilisation |
US8367113B2 (en) | 2006-05-15 | 2013-02-05 | Massachusetts Institute Of Technology | Polymers for functional particles |
US8071082B2 (en) | 2006-07-21 | 2011-12-06 | Massachusetts Institute Of Technology | End-modified poly(beta-amino esters) and uses thereof |
US20100303723A1 (en) | 2006-11-20 | 2010-12-02 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
WO2008124634A1 (fr) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Micelles inverses encapsulées par un polymère |
EP2187896B1 (fr) | 2007-07-31 | 2016-01-13 | The Board of Regents of The University of Texas System | Inhibiteurs de mir-499 et mir-208b pour le traitement de l'hypertrophie cardiaque pathologique, l'infarctus du myocarde ou l'insuffisance cardiaque |
WO2009110939A2 (fr) | 2007-12-10 | 2009-09-11 | Massachusetts Institute Of Technology | Système d'administration de médicament pour produits pharmaceutiques et radiopharmaceutiques |
US7994150B2 (en) | 2008-02-21 | 2011-08-09 | Board Of Regents, The University Of Texas System | Micro-RNAs that modulate smooth muscle proliferation and differentiation and uses thereof |
US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
WO2010042555A2 (fr) | 2008-10-06 | 2010-04-15 | The Brigham And Women's Hospital, Inc. | Particules dotées de plusieurs domaines superficiels fonctionnalisés |
JP6087504B2 (ja) | 2008-11-07 | 2017-03-01 | マサチューセッツ インスティテュート オブ テクノロジー | アミノアルコールリピドイドおよびその使用 |
WO2010120385A1 (fr) | 2009-04-18 | 2010-10-21 | Massachusetts Institute Of Technology | Particules polymères biodégradables sensibles au ph pour la délivrance de médicaments |
EP2524037B1 (fr) | 2010-01-12 | 2018-05-16 | The University Of North Carolina At Chapel Hill | Répétitions terminales inversées restrictives pour vecteurs viraux |
US9517250B2 (en) | 2010-04-28 | 2016-12-13 | The J. David Gladstone Institutes | Methods for generating cardiomyocytes |
WO2011159726A2 (fr) | 2010-06-14 | 2011-12-22 | The Scripps Research Institute | Reprogrammation de cellules pour leur conférer un nouveau destin |
CA2804791C (fr) | 2010-07-08 | 2019-07-30 | Duke University | Reprogrammation directe de cellules en un devenir de cardiomyocytes |
WO2012019168A2 (fr) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Acides nucléiques modifiés et leurs procédés d'utilisation |
EP2622064B1 (fr) | 2010-10-01 | 2019-05-29 | Modernatx, Inc. | Nucléosides, nucléotides et acides nucléiques modifiés et leurs utilisations |
WO2012116064A1 (fr) | 2011-02-22 | 2012-08-30 | The Board Of Regents Of The University Of Texas | Réparation cardiaque par la reprogrammation de fibroblastes cardiaques en cardiomyocytes |
PL2691443T3 (pl) | 2011-03-28 | 2021-08-30 | Massachusetts Institute Of Technology | Sprzężone lipomery i ich zastosowania |
EP2714709B1 (fr) | 2011-05-26 | 2018-04-18 | University of Washington | Compositions pour utilisations dans des procédés basés sur des cellules et des gènes permettant d'améliorer la fonction cardiaque |
WO2013033213A1 (fr) | 2011-08-30 | 2013-03-07 | The J. David Gladstone Institutes | Procédés pour la génération de cardiomyocytes |
US8935819B1 (en) | 2011-09-22 | 2015-01-20 | Rick Hartley | Mattress foundations, kits and related methods |
HRP20220250T1 (hr) | 2011-10-03 | 2022-04-29 | Modernatx, Inc. | Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe |
CN104136419B (zh) | 2011-10-27 | 2017-11-03 | 麻省理工学院 | 能够形成药物封装微球的在n末端上官能化的氨基酸衍生物 |
WO2013078316A1 (fr) | 2011-11-23 | 2013-05-30 | Nationwide Children's Hospital, Inc. | Administration de virus adéno-associé recombinant de polynucléotides alpha-sarcoglycanes |
EP2791160B1 (fr) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Compositions de mrna modifiés |
EP2791210A1 (fr) | 2011-12-16 | 2014-10-22 | Massachusetts Institute of Technology | Polymères d'alpha-aminoamidine et leurs utilisations |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
EP2841056A4 (fr) | 2012-04-23 | 2015-09-16 | Massachusetts Inst Technology | Particules enrobées couche par couche stables |
ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
EP3517612A1 (fr) | 2013-03-15 | 2019-07-31 | The University of North Carolina At Chapel Hill | Répétitions terminales inversées de synthèse du virus adéno-associé |
AU2014290568B2 (en) * | 2013-07-17 | 2020-10-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production |
CN103451284B (zh) * | 2013-08-22 | 2015-03-18 | 中国科学院生物物理研究所 | 一组人类心肌细胞的新型分子标记物及其应用 |
EP3060649A4 (fr) | 2013-10-23 | 2017-07-12 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Reprogrammation de cardiomyocytes à l'aide d'un facteur de transcription |
SG11201705324UA (en) | 2015-01-16 | 2017-07-28 | Univ Washington | Novel micro-dystrophins and related methods of use |
US10648000B2 (en) | 2015-02-16 | 2020-05-12 | University Of Florida Research Foundation, Incorporated | rAAV vector compositions, methods for targeting vascular endothelial cells and use in treatment of type I diabetes |
US9885018B1 (en) | 2015-03-16 | 2018-02-06 | The Regents Of The University Of Colorado, A Body Corporate | High efficiency reprogramming of fibroblasts into cardiomyocytes |
CA2979065A1 (fr) | 2015-03-24 | 2016-09-29 | The Regents Of The University Of California | Variants de virus adeno-associe et leurs procedes d'utilisation |
WO2017173137A1 (fr) | 2016-03-30 | 2017-10-05 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Reprogrammation cardiaque directe améliorée |
WO2018222503A1 (fr) | 2017-05-31 | 2018-12-06 | The Regents Of The University Of California | Virus adéno-associé à capside variante et ses méthodes d'utilisation |
WO2019036086A1 (fr) | 2017-08-15 | 2019-02-21 | The Board Of Regents Of The University Of Texas System | Réparation cardiaque par reprogrammation de fibroblastes cardiaques adulte en cardiomyocytes |
CA3076348A1 (fr) | 2017-09-20 | 2019-03-28 | 4D Molecular Therapeutics Inc. | Virus adeno-associe a variant de capsides et leurs procedes d'utilisation |
BR112021003897A2 (pt) | 2018-08-30 | 2021-05-25 | Tenaya Therapeutics, Inc. | reprogramação de células cardíacas com miocarina e asci1 |
US20200405824A1 (en) | 2019-06-26 | 2020-12-31 | University Of Washington | Use of ribonucleotide reductase alone or in combination with micro-dystrophin to treat duchenne muscular dystrophy striated muscle disease |
US20230137971A1 (en) | 2019-07-11 | 2023-05-04 | Tenaya Therapeutics Inc. | Cardiac cell reprogramming with micrornas and other factors |
KR20220149590A (ko) | 2020-03-02 | 2022-11-08 | 테나야 테라퓨틱스, 인코포레이티드 | 심근세포-발현 마이크로rna에 의한 유전자 벡터 제어 |
-
2019
- 2019-08-30 BR BR112021003897-3A patent/BR112021003897A2/pt unknown
- 2019-08-30 CA CA3111076A patent/CA3111076A1/fr active Pending
- 2019-08-30 JP JP2021536661A patent/JP7450945B2/ja active Active
- 2019-08-30 CN CN201980068063.1A patent/CN113164556A/zh active Pending
- 2019-08-30 SG SG11202102058UA patent/SG11202102058UA/en unknown
- 2019-08-30 KR KR1020217009309A patent/KR20210102870A/ko active Search and Examination
- 2019-08-30 EP EP19853735.9A patent/EP3843774A4/fr active Pending
- 2019-08-30 AU AU2019333315A patent/AU2019333315B2/en active Active
- 2019-08-30 WO PCT/US2019/049150 patent/WO2020047467A2/fr active Application Filing
-
2020
- 2020-09-22 US US17/028,881 patent/US11015211B2/en active Active
-
2021
- 2021-02-28 IL IL281145A patent/IL281145A/en unknown
- 2021-03-24 US US17/211,559 patent/US11913012B2/en active Active
-
2022
- 2022-09-12 AU AU2022231649A patent/AU2022231649A1/en active Pending
-
2023
- 2023-09-15 US US18/468,652 patent/US20240052369A1/en active Pending
- 2023-11-02 JP JP2023188492A patent/JP2024001344A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3111076A1 (fr) | 2020-03-05 |
IL281145A (en) | 2021-04-29 |
US11015211B2 (en) | 2021-05-25 |
EP3843774A4 (fr) | 2022-08-31 |
CN113164556A (zh) | 2021-07-23 |
US20210207170A1 (en) | 2021-07-08 |
BR112021003897A2 (pt) | 2021-05-25 |
AU2022231649A1 (en) | 2022-10-06 |
AU2019333315B2 (en) | 2022-09-29 |
US11913012B2 (en) | 2024-02-27 |
WO2020047467A2 (fr) | 2020-03-05 |
US20240052369A1 (en) | 2024-02-15 |
EP3843774A2 (fr) | 2021-07-07 |
AU2019333315A1 (en) | 2021-03-25 |
WO2020047467A3 (fr) | 2020-07-30 |
JP2024001344A (ja) | 2024-01-09 |
JP2022513308A (ja) | 2022-02-07 |
KR20210102870A (ko) | 2021-08-20 |
JP7450945B2 (ja) | 2024-03-18 |
US20210032659A1 (en) | 2021-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281145A (en) | Reprogramming of cardiac cells with myocardium and ASCL1 | |
EP3634288A4 (fr) | Électrode durcie et fabriquée dans le corps, et méthodes et dispositifs associés | |
IL274200A (en) | Implantable methods, compositions and components containing active cells | |
EP3615046A4 (fr) | Cellules exprimant des récepteurs d'activation chimériques et des récepteurs de stimulation chimériques et utilisations associées | |
EP3531978A4 (fr) | Valvules cardiaques prothétiques dotées de structures de support élastiques et méthodes associées | |
EP3629414A4 (fr) | Batterie flexible et son procédé de préparation | |
IL272715A (en) | Transgenic deoxyribonuclease enzymes and use in medicine | |
EP3652304A4 (fr) | Cellules de donneur universel et procédés associés | |
EP3514879A4 (fr) | Solution électrolytique et batterie | |
IL281810A (en) | Implantable devices for cell therapy and related methods | |
SG11202105173VA (en) | Modified cell expressing therapeutic agent and uses thereof | |
IL298567B1 (en) | Substrate contact independent cells and their uses | |
HUE065308T2 (hu) | Háromdimenziós szerkezetû elektród és az azt tartalmazó elektrokémiai egység | |
IL277673A (en) | Transgenic cells and their uses | |
IL281963A (en) | Microelectrode array and its uses | |
CA185064S (en) | Power and data center | |
EP3629411A4 (fr) | Électrolyte et batterie | |
EP3688144A4 (fr) | Cellules cd1d et tcr-nkt | |
GB201709840D0 (en) | Methods and medical uses | |
SG10201913267YA (en) | Cell mass, cell structure, and three-dimensional tissue body | |
SG11202004529XA (en) | Transformed human cell and use thereof | |
IL276979A (en) | Macro-encapsulation of medicinal cells, devices and methods in their use | |
SG11202010207WA (en) | Catheter assemblies and related methods | |
EP3737392A4 (fr) | Thérapie de reprogrammation cellulaire | |
EP3689431A4 (fr) | Corps en forme de feuille et structure le comprenant |